Table 2 Mean body mass index (BMI) and number of preclinical (CDR = 0) mutation carriers (MCs) and non-mutation carriers (NCs) in 5-year time segments from −25 to 0 years of estimated symptom onset (EYO).

From: Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease

BMI at EYO/no of MCs or NCs

NCs (N = 110)

MCs (N = 120)

−25.0 to −20.1/no

28.6 (25.1–32.2)/15

28.4 (25.6–31.1)/16

−20.0 to −15.1/no

29.4 (26.7–32.1)/24

26.4 (23.7–29.0)/22

−15.0 to −10.1/no

31.7 (28.8–35.1)/25

25.4 (23.2–27.6)/29

−10.0 to −5.1/no

31.9 (28.3–35.6)/24

26.5 (24.7–28.3)/28

−5.0 to 0.0/no

31.1 (26.4–33.7)/22

25.9 (23.7–28.1)/25

  1. Note: Displayed are means and 95% confidence intervals (in parentheses) of body mass index (BMI) and the number of MCs and NCs in 5-year time segments starting from −25 to 0 years of EYO; CDR = Clinical Dementia Rating scale.
Back to article page